A clinical pharmacological study of SK-0403

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221260

Enrollment

Registered

2010-10-08

Start date

2010-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

investigational material(s) Generic name etc : SK-0403 INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : O

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes mellitus who have inadequate glycemic control by diet and/or exercise therapies HbA1C of >= 6.5%, but =126mg/dL, but =200mg/dL

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes mellitus Patients with, or a history of, clinically significant cardiac, renal, hepatic, pulmonary, pancreatic and macrovascular disease Patients who had taken SK-0403

Design outcomes

Primary

Measure	Time frame
Pharmacodynamics and Safety	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026